2020 DIA Annual Meeting Site Gao Yinoqing: Gathering Innovation to Help China's Innovative Drug Trends

"High-rise not only provides long-term capital for enterprises to help enterprise development, but also serves as an intermediate link to provide resources for enterprises and build a biopharmaceutical ecosystem.
October 28th, Co-Chief Investment Officer and Partner Ofo Qing said at the Global Drug Information Conference and Exhibition (DIA).
2020 DIA Annual Meeting was held in Suzhou from October 27th to October 30th.
During the four-day event, leaders from global regulators and academic experts, industry leaders, and capital industry leaders gathered to share new knowledge on innovations in pharmaceutical health research and development in an effort to improve human health and well-being.
The opening ceremony was attended by Xu Jinghe, Deputy Director of the State Drug Administration, Xue Bin, Director of the China Food and Drug International Exchange Center, Dr. Tan Lingshi, Chairman of the DIA Global Board of Directors, Dr. Li Zhengqing, Chairman of the DIA China Annual Meeting, Wang Wei, Managing Director of DIA China, Dr. Theresa Mullin, Deputy Director of the FDA Drug Review and Research Center, and Wang Chen, President of the Beijing Concord Medical College of the Chinese Academy of Medical Sciences.
during the discussion on "China's Innovative Drugs Go To the World - The Impact of China's Innovative Drugs on Global Drug Development", Mr. Yi said that investment institutions had acted as leverage and catalysts for the development of the biopharmaceutical industry.
on the one hand, can provide long-term funds to help enterprise development, on the other hand, but also as an intermediary link for enterprises to allocation the best resources, biomedical-related resources are gathered together.
high-rise from a very early stage of early investment, the representative enterprise is Baiji Shenzhou.
has been investing in Baiji Shenzhou since 2014, and has invested eight rounds to this day, and is baiji Shenzhou's only full-time investor in China.
not only provides financial support, but also helps start-ups organize talent, pool resources, design compensation, and bring together the best people.
estimates that Baiji, which was valued at only about $120 million in 2014, has grown into an industry giant valued at $27.4 billion.
the year to June, the number of employees had grown from 130 in 2014 to 4,200.
" as described in "Long Song Line" 'Yangchun Budze, everything shines', the spring sun shines on the earth, everything recovers and grows, China's biopharmaceutical industry will also usher in a vigorous development.
" Yi Noqing believes that China ushered in a great era of great bonuses for good scientists and engineers.
investment institutions as a link to bring talent into the biopharmaceutical industry and promote the development of the industry.
hope that more enterprises are committed to the world's latest or optimal, based in China, to the world.
it is learned that Gao Yu opened a high-level special area at the exhibition, Baiji Shenzhou, Jia and biological, Yifang biological and other 11 invested enterprises group appearance DIA.
has invested in nearly 200 enterprises in the world's largest health industry, including more than 100 Chinese enterprises with a total investment of more than 150 billion yuan and a total market value of more than 2.5 trillion yuan.
has been in the field of innovative drugs, medical devices, medical services, pharmaceutical outsourcing, pharmaceutical retail and other fields of complete layout, to help more Chinese enterprises to the world.